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Obesity and metabolic syndromes are examples whereby excess energy consumption and energy ﬂux disruptions are causative
agents of increased fatness. Because other, as yet elucidated, cellular factors may be involved and because potential treatments of
these metabolic problems involve systemic agents that are not adipose depot-speciﬁc in their actions, should we be thinking of
adipose depot-speciﬁc (cellular) treatments for these problems? For sure, whether treating obesity or metabolic syndrome, the
characteristics of all adipose depot-speciﬁc adipocytes and stromal vascular cells should be considered. The focus of this paper is
to begin to align metabolic dysfunctions with speciﬁc characteristics of adipocytes.
1.Introduction
Our modern lifestyle has led to the diminished use of
consumed energy and to an increasing population of obese
individuals. Obesity is costly [1, 2], can result in a poor
quality life [2, 3], and causes an early death [1, 2]. Metabolic
syndrome is manifested by many symptoms like elevated
intramyocellular lipid, intramuscular lipid, blood insulin,
glucose, cholesterol, triacylglycerol, increases in blood pres-
sure, risk of cardiovascular disease, and heightened chances
of being diagnosed with type 2 diabetes. The progression of
both obesity and metabolic syndrome is reaching epidemic
proportions[4–9]andappearstooccuratincreasinglyearlier
ages [10]. A general dietary, or metabolic, approach to
combat both obesity and metabolic syndrome has had only
limited success, but both are generally linked to visceral
fat and a host of interacting physiological and pathological
processes (Figure 1, Table 1).
2. Adipose Tissue as a Sink for
ExcessiveFattyAcids
White adipose tissue is critical for the deposition of excessive
fatty acids. Surgical implantation of adipose cells into trans-
genic, adipose-devoid mice reinstated insulin sensitivity, de-
creased plasma glucose levels, and normalized insulin con-
centrations [13]. Adipocyte deﬁciency in human subjects
withcongenitalgeneralizedlipodystrophyistypicallyaccom-
panied by severe insulin resistance, hyperinsulinemia, hyper-
glycemia, hypertriglyceridemia, and fatty livers [14]. It has
been shown that the eﬃciency of adipose tissues acting as
a repository for excess energy is reduced in transgenic mice
which express high levels of preadipose factor-1, resulting in
decreasedadiposetissueandinductionofglucoseintolerance
and hypertriglyceridemia [15]. Transgenic mice, with 99%
less white adipose tissue and inactive brown adipose tissue,
developed insulin resistancemanifested bythreefold elevated
plasmaglucoselevelsand50-to400-foldelevatedinsulinlev-
els [16, 17]. White adipose tissue-speciﬁc proteins, including
perilipinandfat-speciﬁcproteinof27kDa(FSP27),promote
sequestrationoftriglyceridesinadiposetissue,whichreduces
circulatory fatty acid concentration, improving insulin sen-
sitivity in peripheral tissues [18]. FSP27 mediates the for-
mation of unilocular lipid droplet in adipocytes and its
knock-out enhances lipolysis, leading to insulin resistance
















Figure 1: Potential causal agents in visceral obesity and the
metabolic syndrome. The most dramatic form of obesity is char-
acterized by excess visceral adipose tissue, which has been shown
to be related to progression of symptoms of metabolic syndrome
[11]. Among the symptoms of this syndrome is insulin resistance,
which appears to be associated with increases in concentrations of
inﬂammation markers in blood. Morphologically in lipid engorged
adipocytes, the nucleus and the lipid synthetic apparatus of cells is
marginalized and may negatively aﬀect further fat synthesis leading
to hyperglycemia or hypercholesterolemia which is commonly
observed in individuals with metabolic syndrome. Individual
regulatory agents shown have been recently described [12]. DM:
diabetes mellitus; FFA: free fatty acid; MCP-1: monocyte chemo
attractant protein-1; TNF-α: tumor necrosis factor alpha; IL-6:
interleukin 6.
Adipose tissue development is characterized by both ad-
ipocyte hyperplasia and hypertrophy. Limiting adipocyte hy-
perplasia leads to accumulation of lipids in existing adi-
pocytes, resulting in hypertrophy. The proteins downstream
of tyrosine kinases-1 (Dok1) are important for adipogenic
diﬀerentiation and adipocyte hyperplasia. Dok1 activates
p120 Ras GTPase-activating proteins, which inhibit the pro-
liferation of preadipocytes and promote their diﬀerentiation
and lipid accumulation, resulting in hypertrophy of existing
adipocytes [20]. It is known that lipid-laden adipocytes are
correlated with insulin resistance [21].
In summary, adipose tissue functions as a sink for ex-
cessive fatty acids, and the impairment of fatty acid storage
function of adipose tissue results in the deposition of fatty
acids in other tissues, such as key insulin responsive tissues,
muscle and liver, leading to insulin resistance. If metabolic
syndromes (speciﬁcally) are undiagnosed and allowed to
progress, patients will experience persistent hyperinsuline-
mia, resulting in detectable apoptosis of pancreatic β-cells
and Type II diabetes [22].
3. Adipose Depots and MetabolicSyndromes
While visceral adipose tissue appears primarily involved in
metabolic syndromes, there are three other major adipose
depots that also may have a role in the etiology of obesity
and/or metabolic syndrome, including visceral, subcutane-
ous, intermuscular, and intramuscular (including intramy-
ocellular lipid) depots. Not all adipose depots possess the
same physiology, and the distribution of adipocytes within
the four major adipose depots plays a role in the severity of
obesityandultimatelymetabolicsyndromes.Thisisprobably
due to the inherently diﬀerent responses by the collective
populations of diﬀerent types of adipocytes in the distinct
adipose depots.
Obtaining knowledge of how cell populations in depot-
speciﬁc adipose tissue manage the dynamics of energy par-
titioning is of growing importance [23, 24]. However, this
is a diﬃcult area of physiology to grasp as not only are the
adiposedepotsdiﬀerent,butsoaretheadipocytes withinany
one adipose depot [12]. Moreover, because stromal vascular
cells, preadipocytes, and mature adipocytes are sources of
proliferative-competent progeny cells in adipose tissue, the
traditional descriptions of adipogenesis and diﬀerentiation
no longer hold true [12]. This implies that novel experi-
mental designs must be employed in order to address depot-
speciﬁc adipocyte cellularity during development, growth,
and metabolism. To confound matters further, the adipose
tissue stromal vascular content is also depot dependent and
may, in part, dictate the potential of disease severity. Firstly,
these cells may provide preadipocytes for increasing the
number of lipid-assimilation cells in the depot. Also, as the
extent of vascularity and connective tissue composition and
deposition may be under intrinsic control diﬀerent from
the adipocyte itself, stromal vascular cells may become a
key player in adipocyte physiology. For example, connective
tissue deposition and organization are decreased in depots
with a higher proportion of larger adipocytes (internal or
visceral depots). Impaired adipose tissue blood ﬂow associ-
ated with severe adipocyte hypertrophy in these depots may
inducehypoxicconditionswhich,inturn,maydestabilizethe
adipocyte extracellular matrix (ECM) resulting in a number
ofadverseconditions.Also,severeadipocytehypertrophyper
se may adversely inﬂuence both the capillary and adipocyte
ECM stability. All components of adipose tissue depots must
be considered as being potentially involved in adipose tissue-
related disease.
Increasing energy utilization via exercise or weight loss
provides a transient opportunity for energy storage in ex-
isting adipose cells, improves insulin sensitivity, and allows
consumed, but as yet unused glucose, to be stored as lipid.
However, if exercise/weight loss is ineﬃcient, what becomes
of the unutilized glucose? Moreover, is the manifestation of
type II diabetes or hypercholesterolemia an indication of
where feedback inhibition of depot-speciﬁc cellular met-
abolicprocessesexists?Also,isthehypercholesterolemiaseen
in metabolic syndrome caused by the inability of the body to
synthesize lipid from acetate? Moreover, is the manifestation
of type II diabetes or hypercholesterolemia an indication
of where feedback inhibition of depot-speciﬁc cellular met-
abolic processes exists? Careful scrutiny of adipocytes may
well address these questions and will provide knowledge
about speciﬁc populations of adipocytes in the development
of obesity/metabolic syndromes.
4. Targets with Which to Combat Obesityand
Metabolic Syndromes
Figure 2 depicts ﬁve targets for manipulating adipocytes in
order to regulate obesity or metabolic syndrome. Traditional
research and clinical focus has been directed towards (1)Journal of Lipids 3
Table 1: Obesity, metabolic syndrome, adipogenesis, and angiogenesis.
Documented physiology Reference
Moderate obesity is associated with adipocyte hypertrophy, whereas more severe obesity also
involves adipocyte hypertrophy and hyperplasia. In obese pigs, hyperplasia is evident as clusters
of small adipocytes.
[26]
Adipose tissue capillary endothelium changes markedly at the ultrastructural and structural level
with adipocyte hypertrophy and even more so in obesity. Capillary lumen diameters are reduced
considerably. These changes could interfere with the vascular remodeling necessary during
adipocyte hypertrophy.
[27]
Angiogenic capacity was determined by quantifying capillary branch formation from human
subcutaneous and visceral adipose tissue explants. subcutaneous explants had more capillary
sprouting than visceral adipose tissue but this increased sprouting decreased with morbid obesity
representing dysfunctional angiogenesis.
[28]
Angiogenesis associated with subcutaneous adipose tissue and visceral adipose tissue from the
same obese patients was evaluated by laying adipose tissue on chick chorioallanto¨ ıc membranes.
The angiogenic potency of adipose tissue was not depot or fat cell size dependent.
[29]
Pangenomic microarray analysis showed that inﬂammatory markers and acute phase reactants
were overexpressed in obese compared to lean human subcutaneous adipose tissue. Modulation
of the inﬂammatory pathways represents a new therapeutic target for the treatment of obesity and
related complications. Genes associated with adipogenesis, per se, were not diﬀerentially
expressed.
[30]
The development of methods for hypoxia detection in adipose tissue has indicated a hypoxia
response in adipose tissue in obese animals. Adipose tissue hypoxia (ATH) may provide
mechanisms for chronic inﬂammation, macrophage inﬁltration, and mitochondrial dysfunction
among other features in adipose tissue in obesity. Adipose tissue blood ﬂow associated with a
failure in compensatory angiogenesis or vasodilatation may precipitate ATH. Translational
studies in humans are necessary to provide conclusive evidence in support of the ATH concept.
[31]
The development and maintenance of the adipocyte extracellular matrix (ECM) is critical to
maintain the function of the adipocyte. Hypoxia in obesity may destabilize the ECM resulting in a
number of adverse conditions. Adipocyte hypertrophy may adversely inﬂuence the adipocyte
ECM stability.
[32]
A 12 yr study of 11,326 respondents showed that overweight individuals with basal metabolic
indices (BMI) ranging between 25 and 29.9 had 17% less relative risk of mortality than those with
BMI below 18.5 or over 35.
[33]
Weight reduction by 5 to 10% of original weight reduces insulin resistance, blood glucose, blood
lipids, and blood pressure, suggesting that some individuals adapt to the excess weight. [4, 34]
Decline in plasma adiponectin or the rise in C-reactive protein, regardless of obesity, appears to
be a better predictor of metabolic syndrome than obesity alone. [35, 36]
The abatement of metabolic syndrome has been attempted through the use of the two isomers of
congugated linoleic acid. The CLA trans10, cis12 isomer depresses diﬀerentiation of adipocytes
by decreasing expression of peroxisome proliferator-activated receptor γ (PPARγ). The dietary
provision to rats of mixtures of CLA cis9, trans11 and CLA trans10, cis12, produced from
industrial hydrogenation of vegetable oil, abated insulin resistance and normalized glucose
tolerance. However, provision of only CLA trans10, cis12 induced insulin resistance in humans
and mice, even though it was found to reduce adipogenesis. Normalization of glucose tolerance
by the thiazolidinediones (TZD) is mediated by activation of lipogenesis through the
PPARγ-dependent transactivation of GLUT4 genes, which encourage glucose uptake and increase
lipogenesis, rather than the antilipogenic mechanism suggested for CLA trans10, cis12. In
addition, the provision of mixed isomers of CLA to rats, where the CLA cis9, trans11 is a
recognized lipogenic factor, normalized insulin resistance, suggesting that limitations to
lipogenesis may be involved in the manifestation of metabolic syndrome.
[37–42]
and (2), the formation of lipid assimilating adipocytes from
adipocyte precursors (preadipocytes). Moreover, as the stro-
mal vascular cell fraction of any adipose depot may provide
cells of the adipocyte lineage (preadipocytes) a majority of
researchhastraditionallybeenplacedonthiscellpopulation.
Recent interest has been expanding to include mechanisms
in which adipocytes play an active regulatory role in me-
tabolism (3). To this end, data from recent studies suggest
that fetal programming of mesodermal cells may play an
important role in the accumulation of postnatal adipocytes
[25]. Physiological relevant processes as simple as altering
the diet of mothers might regulate adipocyte numbers in
oﬀspring. Alterations in adipocyte numbers have also been








Figure 2: Strategic points in which the study of adipocytes will prove fruitful for obesity and metabolic-related problems. Traditional areas
of concentrated research have focused on cell diﬀerentiation to form lipid-assimilating adipocytes (1), lipid metabolism under a variety of
physiologies and nutrient loads (2), and (more recently) adipocyte production of local and systemic regulatory agents (3). However, new
targets like deciphering the potential mechanisms of mature adipocyte dediﬀerentiation (5) to form proliferative-competent progeny cells
like additional preadipocytes (4) are being carefully evaluated.
postnatally (4). To be sure, the nutritional plane of mothers
during pregnancy results in lower birth weights of babies so
the ability to shift the overall cellular make-up during devel-
opment is not absurd. Moreover, mature adipocyte numbers
may not be as ﬁxed as once thought. Adipocytes might
be able to dediﬀerentiate to form additional proliferative-
competent progeny cells (5) which might add adipocytes
to speciﬁc adipose depots, thereby increasing the lipid load
[12].
Collectively, knowledge gained in any of these areas will
aid us in ﬁnding a possible regulatory point for combating
energy ﬂux-related dysfunctions. Similarly, the observations
contained in Table 1 oﬀer insight into physiological points/
observations whereby research might provide knowledge
regarding alleviation of adverse symptoms of both obesity
and metabolic syndrome. As one example, since adipocytes
are capable of synthesizing and releasing chemical regulators
into the blood that might aﬀect systemic metabolism/phys-
iology, the identiﬁcation of the release/eﬀect mechanism
might then point to a target for regulation (Figures 1 and
2). In light of this, a systemic remediation regimen might be
developed, reducing the eﬀects of adipocyte secretions.
5. Conclusion andPerspectives
Can adipose tissue become the major regulator of body
composition? Why is it that one of the most benign/banal
tissues,adiposetissue,hasbecomeanamazingsourceofstem
cells and systemic regulatory agents and, therefore, controls
of a variety of systemic and local physiological and patho-
logical variables of growth, development, and metabolism?
In the light of current research, this once thought innocuous
tissuehasemergedasatrueorgansystem,andtheseareissues
that have to be addressed in the near future to gain more
understanding regarding obesity, metabolic syndromes, and
adipocytes.
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